Organ Transplant Immune Suppressant Drugs Market to Reach $13.9 Billion by 2035

Organ transplant immune suppressant drugs market is valued at $.3 billion in 2025 and is projected to reach $13.9 billion by 2035, expanding at a CAGR of 5.50% during the forecast period. Growth in this market is strongly driven by rising organ transplantation procedures, increasing prevalence of chronic diseases such as kidney and liver failure, and continuous advancements in immunotherapy-based drug development. According to the World Health Organisation (WHO), more than 100,000 solid organ transplants are performed globally every year, yet the demand significantly exceeds supply, creating sustained reliance on long-term immunosuppressive therapies to prevent organ rejection. Additionally, WHO highlights that kidney failure affects approximately 10% of the global population, further increasing transplant dependency and post-operative drug consumption.

Browse the full report description of “Organ Transplant Immune Suppressant Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, Corticosteroids, Monoclonal & Polyclonal Antibodies, Co-Stimulation Blockers), By Organ Transplant (Kidney, Liver, Heart, Lung, Pancreas, Intestinal, Multi-Organ), By Route of Administration (Oral, Intravenous, Injectable/Subcutaneous), By Therapy Type (Induction Therapy, Maintenance Therapy, Rejection Treatment Therapy), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/organ-transplant-immunosuppressant-drugs-market

This widening gap between organ demand and availability directly supports the long-term expansion of immunosuppressant drug usage worldwide. Among drug classes, Monoclonal & Polyclonal Antibodies, particularly Co-Stimulation Blockers, represent the fastest-growing segment. The adoption of targeted biologics such as belatacept is increasing due to their improved safety profile, reduced nephrotoxicity compared to calcineurin inhibitors, and better long-term graft survival outcomes. These therapies are increasingly being integrated into maintenance immunosuppression protocols in kidney and multi-organ transplant cases. Several strategic developments have further strengthened the market landscape. Key industry developments include:

• In April 2026, Veloxis Pharmaceuticals announced that the U.S. FDA granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel investigational maintenance immunosuppressive agent, for the prophylaxis of heart allograft rejection in patients receiving a heart transplant, building on the recent Orphan Drug Designation granted in January 2026 for prevention of organ rejection in patients receiving a liver transplant to address critical unmet needs in the transplant community.

• In March 2026, Eledon Pharmaceuticals announced that the U.S. FDA granted Orphan Drug Designation to tegoprubart for the prevention of allograft rejection in liver transplantation, adding to the orphan designations tegoprubart previously received for prevention of allograft rejection in pancreatic islet cell transplantation and for treatment of amyotrophic lateral sclerosis (ALS), representing an important milestone for this anti-CD40L antibody investigational immunosuppressant therapy.

Market Coverage

• The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
  • Segment Covered-

o By Drug Class
o By Organ Transplant
o By Route of Administration
o By Therapy Type

• Competitive Landscape – Astellas Pharma Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., and Bristol-Myers Squibb Company.

Key questions addressed by the report.

• What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Organ Transplant Immune Suppressant Drugs Market Report Segment

By Drug Class

• Calcineurin Inhibitors
  • Antiproliferative Agents
  • mTOR Inhibitors
  • Corticosteroids
  • Monoclonal & Polyclonal Antibodies
  • Co-Stimulation Blockers

By Organ Transplant

• Kidney Transplant
  • Liver Transplant
  • Heart Transplant
  • Lung Transplant
  • Pancreas Transplant
  • Intestinal Transplant
  • Multi-Organ Transplant

By Route of Administration

• Oral
  • Intravenous (IV)
  • Injectable/Subcutaneous

By Therapy Type

• Induction Therapy
  • Maintenance Therapy
  • Rejection Treatment Therapy

Global Organ Transplant Immune Suppressant Drugs Market Report Segment by Region

North America

• United States
  • Canada

Europe

• UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

Asia-Pacific

• China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

Rest of the World

• Latin America
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/organ-transplant-immunosuppressant-drugs-market